| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
103.12(B) |
| Last
Volume: |
259,279 |
Avg
Vol: |
765,410 |
| 52
Week Range: |
$692.45 - $993.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
168,566 |
236,471 |
279,472 |
438,206 |
| Total Sell Value |
$164,437,486 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
| Total People Sold |
8 |
14 |
16 |
18 |
| Total Sell Transactions |
15 |
42 |
60 |
120 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bassler Bonnie L |
Director |
– • – |
2021-07-01 |
4 |
OE |
$391.92 |
$1,002,531 |
D/D |
2,558 |
3,449 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-07-01 |
4 |
AS |
$556.60 |
$556,600 |
D/D |
(1,000) |
17,038 |
|
8% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-07-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2021-06-25 |
4 |
AS |
$549.00 |
$1,144,116 |
D/D |
(2,084) |
891 |
|
16% |
|
| Brown Michael S |
Director |
– • – |
2021-06-25 |
4 |
OE |
$371.40 |
$773,998 |
D/D |
2,084 |
2,975 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2021-06-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
211,585 |
0 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2021-06-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
211,585 |
213,693 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2021-06-21 |
4 |
AS |
$532.89 |
$43,112,141 |
I/I |
(80,000) |
2,108 |
|
10% |
|
| Vagelos P Roy |
Director |
– • – |
2021-06-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,000 |
308,090 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2021-06-07 |
4 |
AS |
$525.00 |
$1,013,250 |
D/D |
(1,930) |
5,891 |
|
6% |
|
| Goldstein Joseph L |
Director |
– • – |
2021-06-07 |
4 |
OE |
$374.12 |
$722,052 |
D/D |
1,930 |
7,821 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-06-07 |
4 |
AS |
$511.65 |
$511,650 |
D/D |
(1,000) |
17,038 |
|
6% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-06-07 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2021-05-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
22,000 |
327,090 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2021-05-19 |
4 |
GD |
$0.00 |
$0 |
I/I |
41,178 |
0 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2021-05-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
41,178 |
41,178 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2021-05-17 |
4 |
S |
$518.63 |
$9,101,460 |
D/D |
(17,521) |
24,280 |
|
-22% |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
D |
$516.69 |
$18,073,300 |
D/D |
(34,979) |
41,801 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
OE |
$52.03 |
$7,815,575 |
D/D |
52,500 |
49,005 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-05-07 |
4 |
S |
$495.63 |
$495,630 |
D/D |
(1,000) |
17,038 |
|
-31% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-05-07 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2021-04-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
446 |
142,350 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2021-02-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
435 |
24,280 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2021-02-23 |
4 |
D |
$458.48 |
$63,269,323 |
D/D |
(137,998) |
349,090 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2021-02-23 |
4 |
OE |
$52.03 |
$13,007,500 |
D/D |
250,000 |
487,088 |
|
- |
|
1366 Records found
|
|
Page 23 of 55 |
|
|
4.45 (0.45%) 
